Clin2
NCT07513441Possibly a fitRecruiting

Testing Lu AF28996 for Parkinson's disease motor fluctuations

Parkinson Disease

Part of Brain & nervous system clinical trials.

This early-stage trial tests a new medication called Lu AF28996 in Chinese patients with Parkinson's disease who experience predictable on-off episodes (times when medication works well versus poorly). The study aims to see if this drug can help reduce those difficult off periods.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 1
Enrollment
10 people
Ages
35 years to 85 years
Study type
Interventional

Who can take part

  • You have Parkinson's disease diagnosed by a specialist using standard criteria
  • You are of Chinese descent (all four grandparents born in China)
  • You experience predictable motor fluctuations, including morning off episodes that noticeably affect your daily life in the past 3 months
  • Your Parkinson's severity falls in a specific moderate range (Hoehn and Yahr score 2–4 when off medication, ≤3 when on)
  • You have not taken dopamine agonist medications (pills or patches) or Traditional Chinese Medicine within the last 4 weeks
  • You have not had neurosurgery for Parkinson's (such as deep brain stimulation)

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07432958Recruiting· Phase 2
Study of AP-472 with levodopa for Parkinson's motor fluctuations

This trial tests an experimental drug called AP-472, taken alongside your regular Parkinson's medications, to see if it can reduce the amount of "OFF" time you experience each day when symptoms return between doses of levodopa.

Little Rock, Arkansas
NCT06732180Recruiting· Phase 1
Testing a new drug (GT-02287) for Parkinson's disease

This trial tests an investigational drug called GT-02287 in people with early-stage Parkinson's disease (diagnosed within the last 7 years). The goal is to see if it is safe and how the body processes it, with a special focus on people with certain genetic changes (GBA1 mutations) that may be linked to Parkinson's.

Darlinghurst, New South Wales
NCT07280299Not yet recruiting· Phase 2
Study of GT-02287 for early Parkinson's disease

This trial tests an experimental oral drug called GT-02287 for people with early-stage Parkinson's disease. The study aims to see if the drug can slow progression by targeting a protein linked to Parkinson's, and participants must be willing to have genetic testing and a spinal tap to check for that protein marker.

NCT07156773Recruiting· Phase 2
Nasal spray for Parkinson's off episodes

This study tests a new nasal spray called XJN010 for people with Parkinson's who have 'off' episodes—times when their regular medication wears off and symptoms come back. The goal is to see if the spray can safely and effectively help during those periods.

Guangzhou, Guangdong
NCT05882487Not yet recruiting· Early Phase 1
Study drug KL002 for advanced Parkinson’s disease

This early-phase trial tests how safe and potentially effective KL002 is for people with advanced Parkinson’s disease. It may help reduce Parkinson’s movement symptoms, but the main early goal is safety.

Hangzhou, Zhejiang
NCT06976268Recruiting· Phase 2/Phase 3
Testing BHV-8000 for early Parkinson's disease

This study tests a new once-daily pill called BHV-8000 in people who were recently diagnosed with early Parkinson's disease and are not yet on medication. The goal is to see if it can slow the progression of symptoms and improve quality of life.

Birmingham, Alabama

Hear when a new Parkinson Disease trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.